Last updated on August 2019

A Study To Assess Pharmacodynamics Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.


Brief description of study

This study is to assess the effect of PF 05221304 alone, PF 06865571 alone, the co administration of PF 05221304 and PF 06865571, or placebo on whole liver fat in subjects with NAFLD. In addition, this study will evaluate the safety and tolerability of co administration of PF 05221304 and PF 06865571 along with the effects on selected pharmacodynamics (PD)/exploratory parameters, compared to administration of PF 05221304 alone, PF 06865571 alone, and placebo in adults with NAFLD.

Clinical Study Identifier: NCT03776175

Find a site near you

Start Over

Franco Felizarta, Md

Bakersfield, CA United States
  Connect »

eStudy Site

Chula Vista, CA United States
  Connect »

ProSciento, Inc.

Chula Vista, CA United States
  Connect »

National Research Institute

Los Angeles, CA United States
  Connect »

Pharmax Research Clinic

Miami, FL United States
  Connect »

QPS-MRA, LLC-Main Office

South Miami, FL United States
  Connect »

Qps-Mra, Llc

South Miami, FL United States
  Connect »

L-MARC Research Center

Louisville, KY United States
  Connect »

Clarity Clinical Research

East Syracuse, NY United States
  Connect »

M3 Wake Research, Inc

Raleigh, NC United States
  Connect »

Wake Gastroenterology

Raleigh, NC United States
  Connect »

PMG Research of Wilmington, LLC

Wilmington, NC United States
  Connect »

New Horizons Clinical Research

Cincinnati, OH United States
  Connect »

WR-Clinsearch, LLC

Chattanooga, TN United States
  Connect »

Clinical Trials of Texas, Inc.

San Antonio, TX United States
  Connect »